Inhibikase Therapeutics earnings release, August 11, 2026

Inhibikase Therapeutics, Inc. (IKT) · Form 8-K, Item 2.02 · Filed · SEC filing

Inhibikase Therapeutics Announces Second Quarter 2026

Financial Results and Highlights Recent Activity

WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or

“Company”), a clinical-stage pharmaceutical company developing

IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.

“During our second quarter and in recent weeks we continued to advance our Phase 3

IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive

Officer of Inhibikase. “Also, during the quarter, favorable results of pre-clinical and Phase 1 studies of

IKT-001 were presented at the

American Thoracic

Society International Conference, with data demonstrating improvements in pulmonary vascular and hemodynamic markers of PAH and lower potential for GI toxicity compared to imatinib mesylate. Together with the recent grant of Orphan Drug

Designation from the U.S. FDA and the $50 million proceeds from the sale of shares to RA Capital, Inhibikase is well-positioned to advance

IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”

Recent Developments¹

Presentations

Financial Results

Cash Position:

As of

June 30, 2026, cash, cash equivalents and marketable securities were $159.0 million. Subsequent to the close of the quarter the Company announced that it had sold 25,000,000 shares of the Company’s common stock to RA Capital

Management through its ATM facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in

Part B of the ongoing global Phase 3

IMPROVE-PAH clinical study, assuming the full and timely exercise of the outstanding Series A and B Warrants.

As of June 30, 2026, there were 132.0 million shares of common stock and 42.5 million pre-funded warrants outstanding.

Net Loss:

Net loss for the quarter ended June 30, 2026, was $19.6 million, or $0.11 per share, compared to a net loss of $9.9 million, or $0.11 per share in the quarter ended June 30, 2025. Net loss for the six months ended June 30, 2026, was $36.0 million, or $0.21 per share, compared to a net loss of $23.6 million, or $0.26 per share, for the six months ended June 30, 2025.

R&D Expenses:

Research and development expenses were $13.4 million for the quarter ended June 30, 2026, compared to $5.3 million for the quarter ended June 30, 2025. Research and development expenses were $24.2 million for the six months ended June 30, 2026, compared to $15.8 million for the six months ended June 30, 2025.

SG&A Expenses:

Selling, general and administrative expenses for the quarter ended June 30, 2026 were

$7.7 million, compared to $5.9 million for the quarter ended June 30, 2025. Selling, general and administrative expenses for the six months ended June 30, 2026 were $15.0 million, compared to $11.2 million for the six months ended June 30, 2025, which included $1.0 million of severance expenses for prior senior executives of the Company.²

About Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as

“c-Kit,” has been implicated. Our lead product candidate is

IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named

IMPROVE-PAH

(

I

KT-001 for

M easuring

P ulmonary Vascular

R esistance and

O utcome

V ariables in a Phase 3

E valuation of

PAH), is actively enrolling patients.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases,

SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under

Regulation FD.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Costs and expenses:Research and development13,393,4645,270,96724,232,61415,784,546
Costs and expenses:Selling, general and administrative7,657,5315,919,73115,033,65411,169,022
Costs and expenses:Change in fair value contingent consideration-358,420-373,354-1,523,284
Costs and expenses:Total costs and expenses21,050,99510,832,27838,892,91425,430,284
Costs and expenses:Loss from operations-21,050,995-10,832,278-38,892,914-25,430,284
Costs and expenses:Other income1,459,764916,7552,920,8431,836,026
Costs and expenses:Net loss-19,591,231-9,915,523-35,972,071-23,594,258
Costs and expenses:Other comprehensive income (loss), net of tax Unrealized gain (loss) on marketable securities-46,461-1,977-94,55634,304
Costs and expenses:Comprehensive loss-19,637,692-9,917,500-36,066,627-23,559,954
Costs and expenses:Net loss per share – basic and diluted-0.11-0.11-0.21-0.26
Costs and expenses:Weighted-average number of shares – basic and diluted174,571,54390,009,625173,445,49389,774,703

Balance Sheet

June 30, 2026 — (Unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents31,206,707139,220,208
Current assets:Marketable securities127,812,14039,543,820
Current assets:Prepaid research and development2,346,6411,001,993
Current assets:Prepaid expenses and other current assets933,938343,374
Current assets:Deferred offering costs44,489
Current assets:Total current assets162,343,915180,109,395
Current assets:Prepaid research and development, noncurrent1,000,0001,000,000
Current assets:Other assets244,69795,121
Current assets:Total assets163,588,612181,204,516
Current liabilities:Accounts payable991,7201,158,054
Current liabilities:Accrued expenses and other current liabilities9,268,3064,081,282
Current liabilities:Contingent consideration liability3,061,501
Current liabilities:Total current liabilities10,260,0268,300,837
Current liabilities:Total liabilities10,260,0268,300,837
Stockholders’ equity:Common stock, $0.001 par value; 500,000,000 shares authorized; 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 10) at June 30, 2026 and December 31, 2025, respectively132,032131,691
Stockholders’ equity:Additional paid-in capital331,921,179315,429,986
Stockholders’ equity:Accumulated other comprehensive income (loss)-72,75421,802
Stockholders’ equity:Accumulated deficit-178,651,871-142,679,800
Stockholders’ equity:Total stockholders’ equity153,328,586172,903,679
Stockholders’ equity:Total liabilities and stockholders’ equity163,588,612181,204,516

Cash Flow

Six months ended June 30, — (Unaudited)

Six months ended June 30, – 2026Six months ended June 30, – 2025
Cash flows from operating activitiesNet loss-35,972,071-23,594,258
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation36,812
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense10,905,7766,250,938
Adjustments to reconcile net loss to net cash used in operating activities:Write-off of in-process research and development7,357,294
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value contingent consideration-373,354-1,523,284
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash accretion on marketable securities-1,969,587
Changes in operating assets and liabilities:Operating lease right-of-use assets66,519
Changes in operating assets and liabilities:Prepaid expenses and other current assets-590,5647,526
Changes in operating assets and liabilities:Prepaid research and development-1,344,648-57,547
Changes in operating assets and liabilities:Other assets-149,576
Changes in operating assets and liabilities:Accounts payable-196,3341,592,656
Changes in operating assets and liabilities:Operating lease liabilities-72,573
Changes in operating assets and liabilities:Accrued expenses and other current liabilities5,187,024258,156
Changes in operating assets and liabilities:Net cash used in operating activities-24,503,334-9,677,761
Cash flows from investing activitiesPurchases of equipment and improvements-13,399
Cash flows from investing activitiesPurchases of investments - marketable securities-145,618,289
Cash flows from investing activitiesMaturities of investments - marketable securities59,225,00031,350,103
Cash flows from investing activitiesAcquired in-process research and development-438,624
Cash flows from investing activitiesNet cash provided by (used in) investing activities-86,393,28930,898,080
Cash flows from financing activitiesDeferred offering costs-14,489
Cash flows from financing activitiesProceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs2,897,611150
Cash flows from financing activitiesIssuance of common stock from exercise of options31,621
Cash flows from financing activitiesNet cash provided by financing activities2,883,12231,771
Cash flows from financing activitiesNet increase (decrease) in cash and cash equivalents-108,013,50121,252,090
Cash flows from financing activitiesCash and cash equivalents at beginning of period139,220,20856,490,579
Full release

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,”

“will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential of

IKT-001,... (truncated)the advancement of the Company’s global pivotal Phase 3 clinical study of

IKT-001 in PAH, including the timing, design, initiation and conduct of the

IMPROVE-PAH study and related regulatory submissions, the Company’s ability to obtain additional regulatory approvals for the

IMPROVE-PAH study, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of

IKT-001, the potential benefits of Orphan Drug Designation, the Company’s expectations regarding its cash runway and ability to fund operations through topline data readout in Part B of

IMPROVE-PAH, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate

IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form

10-K and Form

10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.³

Contacts:

Investor Relations:

Michael Moyer

LifeSci Advisors mmoyer@lifesciadvisors.com

---tables to follow---⁴

Inhibikase Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)⁵

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Inhibikase Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.